Gout - 55 Studies Found Recruiting : Novel Methods for Ascertainment of Gout Flares -A Pilot Study : Gout : 2016-07-28 : Device: IVR (Phone call) IVR w Completed : Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. : Acute Gout : 2010-03-02 : Drug: Canakinumab 150 mg Canak Completed : Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study : Acute Gout : 2009-12-09 : Drug: Canakinumab 150 mg Canak Completed : Long-Term Safety of Febuxostat in Subjects With Gout. : Gout : 2005-09-12 : Drug: Febuxostat Febuxostat 40 COMPLETED : Effect of Tigulixostat on the Pharmacokinetics of Theophylline : Gout : 2024-11-21 : 300 mg oral dose NOT_YET_RECRUITING : Reverse Transcriptase Inhibitors in Aicardi Gouti�res Syndrome : Aicardi Gouti�res Syndrome : 2024-11-21 : Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate.This is RECRUITING : Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients : Gout : 2024-11-21 : Xanthine Oxidase Inhibitor RECRUITING : Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare : Acute Gout Flare : 2024-11-21 : An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later RECRUITING : Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout : Gout : 2024-11-21 : Low, medium or high dose (Part 1); Selected dose(s) (Part 2) RECRUITING : Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout : Gout : 2024-11-21 : increasing dose of D-0120 <<< Previous | Next >>>
